J. David Robertson

J. David Robertson

Auto-generated profile, based on publicly available information

J. David Robertson

Department of Chemistry and University of Missouri Research Reactor, University of Missouri, Columbia, MO 65211, USA

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2003 in Circulation
Verified
Journal Article
Closed access
PWPatrick M. Winter
Patrick M. Winter
AMAnne M. Morawski
Anne M. Morawski
SCShelton D. Caruthers
Shelton D. Caruthers
RFRalph W. Fuhrhop
Ralph W. Fuhrhop
HZHuiying Zhang
Huiying Zhang
SWSamuel A. Wickline
Samuel A. Wickline
Background— Angiogenesis is a critical feature of plaque development in atherosclerosis and might play a key role in both the initiation and later rupture of plaques that lead to myocardial infarction and stroke. The precursory molecular or cellular events that initiate plaque growth and that ultimately contribute to plaque instability, however, cannot be detected directly with any current diagnostic modality. Methods and Results— Atherosclerosis was induced in New Zealand White rabbits fed 1% cholesterol for ≈80 days. α v β 3 -Integrin–targeted, paramagnetic nanoparticles were injected intravenously and provided specific detection of the neovasculature within 2 hours by routine magnetic resonance imaging (MRI) at a clinically relevant field strength (1.5 T). Increased angiogenesis was detected as a 47±5% enhancement in MRI signal averaged throughout the abdominal aortic wall among rabbits that received α v β 3 -targeted, paramagnetic nanoparticles. Pretreatment of atherosclerotic rabbits with α v β 3 -targeted, nonparamagnetic nanoparticles competitively blocked specific contrast enhancement of the α v β 3 -targeted paramagnetic agent. MRI revealed a pattern of increased α v β 3 -integrin distribution within the atherosclerotic wall that was spatially heterogeneous along both transverse and longitudinal planes of the abdominal aorta. Histology and immunohistochemistry confirmed marked proliferation of angiogenic vessels within the aortic adventitia, coincident with prominent, neointimal proliferation among cholesterol-fed, atherosclerotic rabbits in comparison with sparse incidence of neovasculature in the control animals. Conclusions— This molecular imaging approach might provide a method for defining the burden and evolution of atherosclerosis in susceptible individuals as well as responsiveness of individual patients to antiatherosclerotic therapies.

10 June 2010 in Nano Letters
Verified
Journal Article
Closed access
RARochelle R. Arvizo
Rochelle R. Arvizo
OMOscar R. Miranda
Oscar R. Miranda
MTMichael A. Thompson
Michael A. Thompson
CPChristina M. Pabelick
Christina M. Pabelick
RBResham Bhattacharya
Resham Bhattacharya
PMPriyabrata Mukherjee
Priyabrata Mukherjee

13 September 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RARochelle R. Arvizo
Rochelle R. Arvizo
OMOscar R. Miranda
Oscar R. Miranda
DMDaniel F. Moyano
Daniel F. Moyano
CWChad A. Walden
Chad A. Walden
KGKaruna Giri
Karuna Giri
PMPriyabrata Mukherjee
Priyabrata Mukherjee
Inorganic nanoparticles provide promising tools for biomedical applications including detection, diagnosis and therapy. While surface properties such as charge are expected to play an important role in their in vivo behavior, very little is known how the surface chemistry of nanoparticles influences their pharmacokinetics, tumor uptake, and biodistribution. Using a family of structurally homologous nanoparticles we have investigated how pharmacological properties including tumor uptake and biodistribution are influenced by surface charge using neutral (TEGOH), zwitterionic (Tzwit), negative (TCOOH) and positive (TTMA) nanoparticles. Nanoparticles were injected into mice (normal and athymic) either in the tail vein or into the peritoneum. Neutral and zwitterionic nanoparticles demonstrated longer circulation time via both IP and IV administration, whereas negatively and positively charged nanoparticles possessed relatively short half-lives. These pharmacological characteristics were reflected on the tumor uptake and biodistribution of the respective nanoparticles, with enhanced tumor uptake by neutral and zwitterionic nanoparticles via passive targeting.

1 September 2006 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PWPatrick M. Winter
Patrick M. Winter
ANAnne M. Neubauer
Anne M. Neubauer
SCShelton D. Caruthers
Shelton D. Caruthers
THThomas D. Harris
Thomas D. Harris
JRJ. David Robertson
J. David Robertson
GLGregory M. Lanza
Gregory M. Lanza
Objective— Angiogenic expansion of the vasa vasorum is a well-known feature of progressive atherosclerosis, suggesting that antiangiogenic therapies may stabilize or regress plaques. α ν β 3 Integrin–targeted paramagnetic nanoparticles were prepared for noninvasive assessment of angiogenesis in early atherosclerosis, for site-specific delivery of antiangiogenic drug, and for quantitative follow-up of response. Methods and Results— Expression of α ν β 3 integrin by vasa vasorum was imaged at 1.5 T in cholesterol-fed rabbit aortas using integrin-targeted paramagnetic nanoparticles that incorporated fumagillin at 0 μg/kg or 30 μg/kg. Both formulations produced similar MRI signal enhancement (16.7%±1.1%) when integrated across all aortic slices from the renal arteries to the diaphragm. Seven days after this single treatment, integrin-targeted paramagnetic nanoparticles were readministered and showed decreased MRI enhancement among fumagillin-treated rabbits (2.9%±1.6%) but not in untreated rabbits (18.1%±2.1%). In a third group of rabbits, nontargeted fumagillin nanoparticles did not alter vascular α ν β 3 -integrin expression (12.4%±0.9%; P >0.05) versus the no-drug control. In a second study focused on microscopic changes, fewer microvessels in the fumagillin-treated rabbit aorta were counted compared with control rabbits. Conclusions— This study illustrates the potential of combined molecular imaging and drug delivery with targeted nanoparticles to noninvasively define atherosclerotic burden, to deliver effective targeted drug at a fraction of previous levels, and to quantify local response to treatment.

21 April 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
NCNripen Chanda
Nripen Chanda
VKVijaya Kattumuri
Vijaya Kattumuri
RSRavi Shukla
Ravi Shukla
AZAjit Zambre
Ajit Zambre
KKKavita Katti
Kavita Katti
RKRaghuraman Kannan
Raghuraman Kannan
Development of cancer receptor-specific gold nanoparticles will allow efficient targeting/optimum retention of engineered gold nanoparticles within tumors and thus provide synergistic advantages in oncology as it relates to molecular imaging and therapy. Bombesin (BBN) peptides have demonstrated high affinity toward gastrin-releasing peptide (GRP) receptors in vivo that are overexpressed in prostate, breast, and small-cell lung carcinoma. We have synthesized a library of GRP receptor-avid nanoplatforms by conjugating gold nanoparticles (AuNPs) with BBN peptides. Cellular interactions and binding affinities (IC 50 ) of AuNP–BBN conjugates toward GRP receptors on human prostate cancer cells have been investigated in detail. In vivo studies using AuNP–BBN and its radiolabeled surrogate 198 AuNP–BBN, exhibiting high binding affinity (IC 50 in microgram ranges), provide unequivocal evidence that AuNP–BBN constructs are GRP-receptor-specific showing accumulation with high selectivity in GRP-receptor-rich pancreatic acne in normal mice and also in tumors in prostate-tumor-bearing, severe combined immunodeficient mice. The i.p. mode of delivery has been found to be efficient as AuNP–BBN conjugates showed reduced RES organ uptake with concomitant increase in uptake at tumor targets. The selective uptake of this new generation of GRP-receptor-specific AuNP–BBN peptide analogs has demonstrated realistic clinical potential in molecular imaging via x-ray computed tomography techniques as the contrast numbers in prostate tumor sites are severalfold higher as compared to the pretreatment group (Hounsfield unit = 150).

25 February 2004 in Magnetic Resonance in Medicine
Verified
Journal Article
Open access
PDF file
AMAnne M. Morawski
Anne M. Morawski
PWPatrick M. Winter
Patrick M. Winter
KCKathryn C. Crowder
Kathryn C. Crowder
SCShelton D. Caruthers
Shelton D. Caruthers
RFRalph W. Fuhrhop
Ralph W. Fuhrhop
SWSamuel A. Wickline
Samuel A. Wickline
Before molecular imaging with MRI can be applied clinically, certain problems, such as the potential sparseness of molecular epitopes on targeted cell surfaces, and the relative weakness of conventional targeted MR contrast agents, must be overcome. Accordingly, the conditions for diagnostic conspicuity that apply to any paramagnetic MRI contrast agent with known intrinsic relaxivity were examined in this study. A highly potent paramagnetic liquid perfluorocarbon nanoparticle contrast agent (∼250 nm diameter, >90000 Gd3+/particle) was imaged at 1.5 T and used to successfully predict a range of sparse concentrations in experimental phantoms with the use of standard MR signal models. Additionally, we cultured and targeted the smooth muscle cell (SMC) monolayers that express “tissue factor,” a glycoprotein of crucial significance to hemostasis and response to vascular injury, by conjugating an anti‐tissue factor antibody fragment to the nanoparticles to effect specific binding. Quantification of the signal from cell monolayers imaged at 1.5 T demonstrated, as predicted via modeling, that only picomolar concentrations of paramagnetic perfluorocarbon nanoparticles were required for the detection and quantification of tissue factor at clinical field strengths. Thus, for targeted paramagnetic agents carrying high payloads of gadolinium, it is possible to quantify molecular epitopes present in picomolar concentrations in single cells with routine MRI. Magn Reson Med 51:480–486, 2004.